News

High importance

EXO Biologics & ExoXpert achieve two critical industry-first milestones for the exosome field

High importance

EXO Biologics completes dosing of first cohort in first EMA-approved MSC-based exosome clinical trial

EXO Biologics secures up to EUR 16 million in Series A funding for exosome therapeutic development and clinical supply.

High importance

ExoXpert, a CDMO launched by EXO Biologics to service increasing worldwide demand for exosomes

Research Paper : EVs From MS Umbilical Cord Cells Exert Protection Against Oxidative Stress and Fibrosis in a Rat Model of BPD

High importance

EXO Biologics Pioneers with EVENEW Clinical Trial in Broncho Pulmonary Dysplasia.

EXO Biologics Granted Orphan Drug Designation by FDA for EXOB-001 for Prevention of BPD in Preterm newborns.

EXO Biologics Received FDA Rare Pediatric Disease Designation for EXOB-001 for Prevention of BPD in Preterm newborns.

EXO Biologics Secures a Total of €8.7 Million in Financing

About us

EXO Biologics mission is to provide affordable and accessible exosomes therapy to patients with unmet medical needs.

Learn more

Logo ExoBiologics